Lessons learned from External Quality Assessment for BRCA and other HRR gene variants for ovarian and prostate cancer

This white paper distils the key lessons from the 2023 EMQN worldwide External Quality Assessment (EQA) scheme, helping genetic testing laboratories improve the accuracy, consistency, and clinical relevance of BRCA and HRR gene variant testing for ovarian and prostate cancer. It summarises common challenges observed across participating labs and provides practical guidance on variant detection, classification, interpretation, and reporting to support higher‑quality diagnostic outcomes globally.